Project Management Institute to Kick Off New Virtual Experience Series 29 July with Host Tamron Hall and Chef José Andrés
22.7.2020 16:30:00 EEST | Business Wire | Press release
Today Project Management Institute (PMI), the world's leading association for the project management profession, launched the new Virtual Experience Series to introduce professionals from all industries to innovative global voices and energize them to bring big ideas to life.
This groundbreaking new series, which is open to the public, connects participants with global innovators, inspirational voices and project leaders who will deliver 40 power-packed sessions to help those who want to boost their career or pivot to a new one. During the series, participants can connect with peers, mentors, experts and renowned public figures alike to gain insights on how to move their careers and projects forward and embrace the great potential and opportunity ahead of us.
Hosted by journalist, talk show host and executive producer Tamron Hall, the series’ six virtual experiences begin 29 July 2020 and continue through 9 December 2020. The first live 4.5-hour experience, titled “The Individual: My Work, My Life, My World” will feature renowned chef and humanitarian José Andrés; author and The New York Times podcast host Priya Parker; and more than 40 industry experts who will inspire, inform, engage and entertain.
During the opening session, José Andrés will discuss how he taps into his inner project manager to help feed the world. In 2010, he formed World Central Kitchen, a non-profit specializing in delivering food relief in the wake of natural and humanitarian disasters. World Central Kitchen has responded to dozens of disasters worldwide and distributed tens of millions of meals. In response to COVID-19, Andrés has partnered with restaurants, small farms and community leaders worldwide to combat food insecurity.
During the first-ever PMI Book Club, Bob Safian, podcast host and former Fast Company editor-in-chief, will chat with Priya Parker, author of “The Art of Gathering: How We Meet and Why it Matters.” Parker will share her inspired strategies for gathering global teams to get meaningful results from your virtual face-to-face meetings.
Each monthly experience will feature a new roster of celebrities and industry experts. Upcoming series dates and topics include:
● 29 July 2020 at 9 a.m. -1:30 p.m. EDT - The Individual: My Work, My Life, My World
● 25 August - The Community: Together We Rise
● 9 September - A Deep Dive in Organizational Agility: Adaptability, Resilience and Learning
● 20 October - The World: Our Global Impact
● 12 November - A Deep Dive in Business Analysis: Drawing a Map to the Future
● 9 December - The Future: Forging Our Path Forward
Registration for PMI members is $99 for a single experience or $359 for the entire series. Registration for non-members is $149 for a single experience or $899 for the event series. Purchasing a series pass includes complimentary on-demand access to PMI’s Talent and Technology Symposium, which took place in June. Each session is eligible for professional development units (PDUs) toward maintaining your PMI certification.
For more information on this event and to register, visit experience.pmi.org.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org, www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005274/en/
Contact information
Media Contact: Mary Ortega, mary.ortega@pmi.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom